280110-76-1

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride is used as a potential candidate in drug development for its unique structural properties that may contribute to the creation of new therapeutic agents.
Used in Chemical Research:
In the field of chemical research, 2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride serves as a valuable research tool for studying the effects of heterocyclic compounds on biological systems, potentially leading to insights into new mechanisms of action or therapeutic targets.
Used in Medicinal Chemistry:
2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride is utilized as a building block or intermediate in the synthesis of more complex molecules with potential medicinal properties, leveraging its heterocyclic nature to explore novel pharmacological activities.
Used in Drug Delivery Systems:
2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride may also be employed in the design of drug delivery systems, where its enhanced solubility and bioavailability could improve the pharmacokinetics and therapeutic efficacy of associated drug molecules.

Upstream product

• 280110-69-2 4-(5-methyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.